ARK Investment Management Crispr Therapeutics Agnamen Akt ownership

Crispr Therapeutics Agnamen Akt's ticker is CRSP and the CUSIP is H17182108. A total of 72 filers reported holding Crispr Therapeutics Agnamen Akt in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.

ARK Investment Management ownership history of Crispr Therapeutics Agnamen Akt
ValueSharesWeighting
Q2 2022$564,758
-4.3%
9,728,831
+3.4%
3.34%
+35.5%
Q1 2022$590,376
-14.3%
9,405,371
+3.5%
2.46%
+18.3%
Q4 2021$688,778
-18.9%
9,089,168
+19.8%
2.08%
+2.1%
Q3 2021$849,064
-32.6%
7,585,674
-2.4%
2.04%
-13.0%
Q2 2021$1,258,876
+24.6%
7,776,119
-6.2%
2.34%
+16.7%
Q1 2021$1,010,179
-36.6%
8,290,350
-20.4%
2.01%
-52.7%
Q4 2020$1,594,331
+125.4%
10,412,976
+23.1%
4.24%
+1.1%
Q3 2020$707,370
+48.5%
8,457,320
+30.4%
4.20%
-18.1%
Q2 2020$476,454
+162.1%
6,483,251
+51.3%
5.12%
+13.1%
Q1 2020$181,754
+0.9%
4,285,632
+44.9%
4.53%
-0.3%
Q4 2019$180,074
+57.9%
2,956,635
+6.3%
4.54%
+82.5%
Q3 2019$114,040
-11.1%
2,782,140
+2.1%
2.49%
-23.0%
Q2 2019$128,317
+77.6%
2,724,349
+34.7%
3.23%
+56.6%
Q1 2019$72,262
+90.9%
2,023,017
+52.7%
2.06%
+34.4%
Q4 2018$37,858
-41.3%
1,325,110
-8.8%
1.54%
-21.1%
Q3 2018$64,467
+134.9%
1,453,590
+211.2%
1.95%
+93.6%
Q2 2018$27,449
+727.8%
467,140
+544.0%
1.01%
+509.7%
Q1 2018$3,316
+349.9%
72,534
+131.1%
0.16%
+179.7%
Q4 2017$737
+257.8%
31,388
+143.5%
0.06%
+47.5%
Q2 2017$20612,8880.04%